PE20190841A1 - Vacuna de adn tolerogenica - Google Patents

Vacuna de adn tolerogenica

Info

Publication number
PE20190841A1
PE20190841A1 PE2019000889A PE2019000889A PE20190841A1 PE 20190841 A1 PE20190841 A1 PE 20190841A1 PE 2019000889 A PE2019000889 A PE 2019000889A PE 2019000889 A PE2019000889 A PE 2019000889A PE 20190841 A1 PE20190841 A1 PE 20190841A1
Authority
PE
Peru
Prior art keywords
dna vaccine
tolerogenic
tolerogenic dna
diabetes
prevention
Prior art date
Application number
PE2019000889A
Other languages
English (en)
Inventor
Jay Chaplin
Michael Wijaranakula
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Priority claimed from PCT/EP2017/077949 external-priority patent/WO2018083111A1/en
Publication of PE20190841A1 publication Critical patent/PE20190841A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/65—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression using markers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55533—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)

Abstract

La presente invencion se refiere a plasmidos utiles para la prevencion y/o el retraso, por ejemplo, de la diabetes tipo 1
PE2019000889A 2016-11-01 2017-11-01 Vacuna de adn tolerogenica PE20190841A1 (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662415717P 2016-11-01 2016-11-01
EP17150037 2017-01-02
EP17169019 2017-05-02
EP17177289 2017-06-22
EP17198041 2017-10-24
PCT/EP2017/077949 WO2018083111A1 (en) 2016-11-01 2017-11-01 Tolerogenic dna vaccine

Publications (1)

Publication Number Publication Date
PE20190841A1 true PE20190841A1 (es) 2019-06-17

Family

ID=60190888

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2019000889A PE20190841A1 (es) 2016-11-01 2017-11-01 Vacuna de adn tolerogenica

Country Status (24)

Country Link
US (1) US11466278B2 (es)
EP (3) EP3799882A1 (es)
JP (3) JP6721790B2 (es)
KR (1) KR102476552B1 (es)
CN (3) CN109890967B (es)
AU (1) AU2017353323B2 (es)
BR (1) BR112019007408A2 (es)
CA (1) CA3042321A1 (es)
CL (1) CL2019001181A1 (es)
CO (1) CO2019004193A2 (es)
DK (1) DK3534936T3 (es)
ES (2) ES2829574T3 (es)
HR (1) HRP20201710T1 (es)
HU (1) HUE051766T2 (es)
IL (1) IL266237B (es)
MX (1) MX2019004774A (es)
MY (1) MY190102A (es)
PE (1) PE20190841A1 (es)
PH (1) PH12019500851A1 (es)
PL (1) PL3534936T3 (es)
RS (1) RS61138B1 (es)
RU (1) RU2752608C2 (es)
SA (1) SA519401615B1 (es)
SI (1) SI3534936T1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
EP3799882A1 (en) * 2016-11-01 2021-04-07 Novo Nordisk A/S Tolerogenic dna vaccine
US11279745B2 (en) 2019-04-26 2022-03-22 Novo Nordisk A/S Tolerogenic DNA vaccine
CN113461796A (zh) * 2021-08-04 2021-10-01 深圳晶蛋生物医药科技有限公司 一种重组sglt2蛋白及其应用
EP4340855A1 (en) * 2021-08-13 2024-03-27 Triovance Holding LLC A skin substitute composition and methods of producing and using the same

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9518395D0 (en) * 1995-09-08 1995-11-08 Therexsys Ltd Plasmid stabilization
WO1998024469A1 (en) 1996-12-05 1998-06-11 University Of Florida Il-10 and tgf-beta for treating autoimmune disease
US7030098B2 (en) 1999-03-12 2006-04-18 The Board Of Trustees Of The Leland Stanford Junior University DNA vaccination for treatment of autoimmune disease
US6884785B2 (en) 1999-06-17 2005-04-26 The Scripps Research Institute Compositions and methods for the treatment or prevention of autoimmune diabetes
WO2001081404A2 (en) 2000-04-20 2001-11-01 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services INDUCIBLE PLASMID VECTOR ENCODING TGF-β AND USES THEREOF
AU2001292610A1 (en) * 2000-09-08 2002-03-22 University Of Maryland Biotechnology Institute Genetically engineered co-expression dna vaccines, construction methods and uses thereof
USD459798S1 (en) 2001-03-26 2002-07-02 Aventis Pharma S.A. Pill tablet
SE0102204D0 (sv) 2001-06-21 2001-06-21 Leif Isaksson New method
EP2301552A1 (en) * 2001-11-21 2011-03-30 The Board Of Trustees Of The Leland Stanford Junior University Polynucleotide therapy
WO2004007664A2 (en) 2002-05-28 2004-01-22 Maxygen, Inc. Nucleic acid vectors
RU2228198C1 (ru) * 2002-08-21 2004-05-10 Полетаев Александр Борисович Способ коррекции патологического аутоиммунного процесса при сахарном диабете
CN100546657C (zh) 2002-11-21 2009-10-07 贝希尔治疗学股份有限公司 预防和治疗疾病的方法及免疫调节核酸组合物
US20050026189A1 (en) 2003-05-29 2005-02-03 Liangsu Wang Microbial operons
US20050147621A1 (en) 2003-10-10 2005-07-07 Higgins Darren E. Use of bacterial 5' untranslated regions for nucleic acid expression
WO2005089101A2 (en) 2004-02-03 2005-09-29 Dana-Farber Cancer Institute, Inc. Non-pathogenic listeria vaccine vectors and methods of treatment therewith
WO2007016764A1 (en) 2005-08-06 2007-02-15 Qinghua Wang Composition and method for prevention and treatment of type i diabetes
AU2006302477A1 (en) 2005-10-05 2007-04-19 Bayhill Therapeutics, Inc. Compositions and methods for treatment of autoimmune disease
CA2550133A1 (en) 2006-02-16 2007-08-16 The Governors Of The University Of Alberta Temperature regulated gene expression
US20100048679A1 (en) 2006-06-13 2010-02-25 Bayhill Therapeutics, Inc. Polynucleotide therapy
US9339500B2 (en) 2008-03-04 2016-05-17 Intra-Cellular Therapies, Inc. Methods of treating vasomotor symptoms
JP5918125B2 (ja) 2009-05-22 2016-05-18 メリアル リミテッド 抗生物質フリープラスミド
US8728456B2 (en) 2009-07-31 2014-05-20 President And Fellows Of Harvard College Programming of cells for tolerogenic therapies
WO2011091138A1 (en) 2010-01-20 2011-07-28 Bayhill Therapeutics, Inc. Combination therapy to treat autoimmune diseases
EP2621522A2 (en) 2010-09-27 2013-08-07 China Agricultural University Combined antigen and dna vaccine for preventing and treating autoimmune diseases
WO2012062697A1 (en) 2010-11-08 2012-05-18 Novartis Ag Combination therapy for type 1 diabetes
EP2753362A4 (en) 2011-09-08 2015-04-15 Univ Florida MATERIALS AND METHODS FOR MODULATING THE IMMUNE RESPONSE
CA2883227A1 (en) 2012-08-29 2014-03-06 Nature Technology Corporation Dna plasmids with improved expression
US9636386B2 (en) 2013-03-15 2017-05-02 City Of Hope Attenuated Salmonella bacteria and methods of using
WO2016057986A1 (en) * 2014-10-10 2016-04-14 The Trustees Of Columbia University In The City Of New York Tandem epitope constructs for presentation of cd4 and cd8 epitopes and uses thereof
WO2016162385A1 (en) 2015-04-07 2016-10-13 Consejo Superior De Investigaciones Científicas (Csic) Bacterial system for the identification of amyloidogenic peptides and the screening of inhibitors of amyloidosis
JP6828038B2 (ja) 2015-12-11 2021-02-10 ワッカー ケミー アクチエンゲゼルシャフトＷａｃｋｅｒ Ｃｈｅｍｉｅ ＡＧ 低分子量物質およびタンパク質の抗生物質を含まない発酵製造のための微生物株および方法
TWI728201B (zh) 2016-11-01 2021-05-21 丹麥商諾佛 儂迪克股份有限公司 耐受性ｄｎａ疫苗
EP3799882A1 (en) * 2016-11-01 2021-04-07 Novo Nordisk A/S Tolerogenic dna vaccine
USD813372S1 (en) 2017-02-22 2018-03-20 Celgene Corporation Pharmaceutical tablet
US11279745B2 (en) 2019-04-26 2022-03-22 Novo Nordisk A/S Tolerogenic DNA vaccine

Also Published As

Publication number Publication date
IL266237B (en) 2022-08-01
HRP20201710T1 (hr) 2020-12-25
CO2019004193A2 (es) 2019-07-31
CN109922827A (zh) 2019-06-21
EP3799882A1 (en) 2021-04-07
AU2017353323B2 (en) 2024-02-29
JP2019532660A (ja) 2019-11-14
EP3534936A1 (en) 2019-09-11
JP7084388B2 (ja) 2022-06-14
US20190241898A1 (en) 2019-08-08
PH12019500851A1 (en) 2019-12-02
HUE051766T2 (hu) 2021-03-29
ES2834329T3 (es) 2021-06-17
BR112019007408A2 (pt) 2019-07-02
RS61138B1 (sr) 2020-12-31
EP3535399B1 (en) 2020-10-07
IL266237A (en) 2019-06-30
RU2752608C2 (ru) 2021-07-29
AU2017353323A1 (en) 2019-05-02
PL3534936T3 (pl) 2021-01-25
ES2829574T3 (es) 2021-06-01
DK3534936T3 (da) 2020-11-02
KR102476552B1 (ko) 2022-12-13
JP2019532659A (ja) 2019-11-14
KR20190076020A (ko) 2019-07-01
CN109890967A (zh) 2019-06-14
SI3534936T1 (sl) 2020-12-31
MY190102A (en) 2022-03-28
CN118086388A (zh) 2024-05-28
SA519401615B1 (ar) 2023-01-31
RU2019115540A3 (es) 2021-01-28
CN109890967B (zh) 2024-03-19
MX2019004774A (es) 2019-08-05
CN109922827B (zh) 2024-03-01
CA3042321A1 (en) 2018-05-11
JP2020062057A (ja) 2020-04-23
EP3535399A1 (en) 2019-09-11
JP6721790B2 (ja) 2020-07-15
RU2019115540A (ru) 2020-12-03
US11466278B2 (en) 2022-10-11
EP3534936B1 (en) 2020-10-21
CL2019001181A1 (es) 2019-07-05

Similar Documents

Publication Publication Date Title
PE20190841A1 (es) Vacuna de adn tolerogenica
CY1124004T1 (el) Υποδορια σκευασματα αντισωματων αντι-cd38 και οι χρησεις τους
BR112017024123A2 (pt) construtos de expressão e métodos de manipulação por engenharia genética de levedura metilotrófica
PH12016501966B1 (en) Compounds and compositions as toll-like receptor 7 agonists
EA201691911A1 (ru) Быстродействующие композиции инсулина
BR112017010173A2 (pt) composição para tratamento de tecido
MY186585A (en) Binding molecules directed against influenza hemagglutinin and uses thereof
CY1124425T1 (el) Συνθεσεις οι οποιες περιλαμβανουν συζευγματα φαρμακου αντισωματος-δουοκαρμυκινης
BR112018003019A2 (pt) vacinas terapêuticas contra hpv18
BR112016025819A2 (pt) vetores de vírus adeno-associados para o tratamento de doenças de depósito lisossômico
MA40902B1 (fr) Vaccins hpv16 thérapeutiques
BR112017010177A2 (pt) composição para tratamento de tecido
PH12019501359A1 (en) Polymorphs
BR112019010131A2 (pt) entrega transdérmica de agentes grandes
IL263574A (en) calr and jak2 preparations
CY1125143T1 (el) Νεα αλατα νιλοτινιμπης και πολυμορφα αυτων
DOP2016000202A (es) Proteínas de fusión uti
CL2019001038A1 (es) Composición para el cuidado bucal.
UY36217A (es) Compuestos piridona sustituídos, composiciones farmacéuticas y métodos de uso.
TR201901516T4 (tr) Nöroprotektif ajanlar ve bunların kullanımları.
BR112018012851A2 (pt) cepas de expressão de proteína melhoradas
CL2016001763A1 (es) Antagonistas selectivos de nr2b
MX2018014955A (es) Vacunas atenuadas vivas del virus de la influenza equina.
CL2017001159A1 (es) Composiciones farmacéuticas de larga duración para la hepatitis c
BR112016017644A2 (pt) conjugados de fator vii